Tag: NYSE: TEVA

Business

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Bioeq AG Announce Viable Collaboration for Biosimilar

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Bioeq AG today announced that they have arrived into a premeditated Collaboration for the particular commercialization of Bioeq’sBioeq’s FYB201, a biosimilar applicant to Lucentis® in Europe, Canada, Israel, and New Zealand. The agreement comprises commercializing biosimilar applicant of ophthalmology medication ranibizumab  This intentional […]

Business

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) And St Josef Hospital release COBRA Study Results

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and St. Josef Hospital have presented the results of the COBRA study at EAN Congress and offered new insight regarding COPAXONE® (glatiramer acetate) use in breastfeeding mothers with multiple sclerosis. The study evaluated 120 mothers and their infants.  The study assessed 120 moms with […]

Business

Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) Releases Study Results Showing Socio-Economic Status Contributes to Migraine Under-Diagnosis

Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) shares dropped after the company presented new epidemiology findings on migraine from Israel, indicating that socio-economic factors can lead to migraine underdiagnosis in society. Disparities exist in migraine diagnosis related to socio-economic status A retrospective migraine epidemiology study in Southern Israel, funded by Teva, […]